The following information is disclosed in accordance with Rule 26 of the AIM Rules (January 2021). These requirements were last reviewed and updated by the Company on 08 April 2024.

Description of BusinessRedx Pharma plc was formed in 2010 and is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis. The Company’s accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions.
Incorporation & Registered OfficeRedx Pharma plc is registered in England & Wales number 07368089
Block 33, Mereside, Alderley Park, Macclesfield, SK10 4TG, UK
DirectorsDr Jane Griffiths (Chair)
Lisa Anson (CEO)
Peter Presland (Non-Executive Director)
Dr Bernhard Kirschbaum (Non-Executive Director)
Dr Joseph Anderson (Non-Executive Director)
Natalie Berner (Non-Executive Director)
Dr Rob Scott (Non-Executive Director)
View Directors’ biographies
AdvisorsNominated Advisor
SPARK Advisory Partners Limited
5 St. John’s Lane
London EC1M 4BH, UK

Broker
Panmure Gordon (UK) Limited
One New Change
London EC4M 9AF, UK

Auditor
Ernst & Young LLP
One Cambridge Business Park
Cowley Road
Cambridge CB4 0WZ, UK

Financial Communications Advisor
FTI Consulting
200 Aldersgate Street
London EC1A 4HD, UK
Legal Advisor
Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ, UK

Registrar
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex BN99 6DA, UK
Corporate GovernanceThe Board seeks to follow best practice in corporate governance appropriate with the size and regulatory framework that applies to AIM companies. The Board reviews and applies the principles and provisions of the 2018 Quoted Company Alliance Corporate Governance Code (“Code”) where it is appropriate to do so to support the governance framework. The main features of the Group’s corporate governance arrangements are:

  • The Board of Directors intends to meet 8 times per year for formal Board Meetings. It approves financial statements, dividends and significant changes in accounting practices and key commercial matters, such as decisions to be taken on whether to take forward or to cancel a scientific project.

  • The membership of the different committees is as to the right.

  • Changes to these committees were implemented 8 March 2022.
Audit, Risk and Disclosure Committee
Peter Presland (C) and Rob Scott

Committee terms of reference PDF

Remuneration Committee
Bernhard Kirschbaum (C) and Peter Presland

Committee terms of reference PDF

Science Committee
Bernhard Kirschbaum (C), Rob Scott and Lisa Anson

Committee terms of reference PDF
Constitutional DocumentsArticles of Association PDF
Exchanges & Trading PlatformsThe Company is not listed on any other Exchanges or Trading Platforms.
Shares & Significant ShareholdersTotal number of shares issued: 388,985,916
Number of shares (if any) held in treasury: Nil

Shareholders with >3% of total issued:
NameNumber of sharesPercentage of issued shares
Funds Managed by Redmile Group, LLC276,890,31971.18%
Sofinnova Crossover I SLP51,948,30713.35%
Invus Public Equities L.P15,203,8153.91%
Last updated 08/04/2024
Shares Not in Public HandsPursuant to the AIM Rules, and insofar as the Company is aware, as at 08/04/2024, 84.63% of the Company’s AIM securities were not in public hands.
Share RestrictionsThere are no restrictions on the transfer of securities.
Admission DocumentCompany admission document PDF
Shareholder CircularsClick to view Shareholder Circulars
Takeover CodeThe Company is subject to the UK City Code on Takeovers and Mergers.
Latest Annual ReportClick to view the latest annual report
RNS AnnouncementsClick to view the company’s RNS Announcements